BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32041674)

  • 1. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
    Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
    Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor.
    Kampilafkos P; Melachrinou M; Kefalopoulou Z; Lakoumentas J; Sotiropoulou-Bonikou G
    Am J Dermatopathol; 2015 Feb; 37(2):138-44. PubMed ID: 25614949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
    Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
    J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezh2
    Zimmerman SM; Nixon SJ; Chen PY; Raj L; Smith SR; Paolini RL; Lin PN; Souroullas GP
    Oncogene; 2022 Nov; 41(46):4983-4993. PubMed ID: 36220978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
    Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
    Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
    He LJ; Cai MY; Xu GL; Li JJ; Weng ZJ; Xu DZ; Luo GY; Zhu SL; Xie D
    Asian Pac J Cancer Prev; 2012; 13(7):3173-8. PubMed ID: 22994729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
    Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
    J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
    Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
    Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
    Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
    Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
    Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ
    Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3.
    Luo H; Jiang Y; Ma S; Chang H; Yi C; Cao H; Gao Y; Guo H; Hou J; Yan J; Sheng Y; Ren X
    Biochem Biophys Res Commun; 2016 Oct; 479(2):253-259. PubMed ID: 27638307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas.
    Ishi Y; Takamiya S; Seki T; Yamazaki K; Hida K; Hatanaka KC; Ishida Y; Oda Y; Tanaka S; Yamaguchi S
    Brain Tumor Pathol; 2020 Jul; 37(3):81-88. PubMed ID: 32529280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
    Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
    BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
    Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
    Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
    Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
    Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of EZH2 in Merkel cell carcinoma is associated with disease progression and poorer prognosis.
    Harms KL; Chubb H; Zhao L; Fullen DR; Bichakjian CK; Johnson TM; Carskadon S; Palanisamy N; Harms PW
    Hum Pathol; 2017 Sep; 67():78-84. PubMed ID: 28739498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
    Samal S; Patnaik A; Sahu F; Purkait S
    Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.